Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells

Nathaniel J. Hart, Woo Jin Chung, Craig Weber, Kameswari Ananthakrishnan, Miranda Anderson, Renata Patek, Zhanyu Zhang, Sean W Limesand, Josef Vagner, Ron Lynch

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

G protein-coupled receptor (GPCR) cell signalling cascades are initiated upon binding of a specific agonist ligand to its cell surface receptor. Linking multiple heterologous ligands that simultaneously bind and potentially link different receptors on the cell surface is a unique approach to modulate cell responses. Moreover, if the target receptors are selected based on analysis of cell-specific expression of a receptor combination, then the linked binding elements might provide enhanced specificity of targeting the cell type of interest, that is, only to cells that express the complementary receptors. Two receptors whose expression is relatively specific (in combination) to insulin-secreting pancreatic β-cells are the sulfonylurea-1 (SUR1) and the glucagon-like peptide-1 (GLP-1) receptors. A heterobivalent ligand was assembled from the active fragment of GLP-1 (7-36 GLP-1) and glibenclamide, a small organic ligand for SUR1. The synthetic construct was labelled with Cy5 or europium chelated in DTPA to evaluate binding to β-cells, by using fluorescence microscopy or time-resolved saturation and competition binding assays, respectively. Once the ligand binds to β-cells, it is rapidly capped and presumably removed from the cell surface by endocytosis. The bivalent ligand had an affinity approximately fivefold higher than monomeric europium-labelled GLP-1, likely a result of cooperative binding to the complementary receptors on the βTC3 cells. The high-affinity binding was lost in the presence of either unlabelled monomer, thus demonstrating that interaction with both receptors is required for the enhanced binding at low concentrations. Importantly, bivalent enhancement was accomplished in a cell system with physiological levels of expression of the complementary receptors, thus indicating that this approach might be applicable for β-cell targeting in vivo.

Original languageEnglish (US)
Pages (from-to)135-145
Number of pages11
JournalChemBioChem
Volume15
Issue number1
DOIs
StatePublished - Jan 3 2014

Fingerprint

Glucagon-Like Peptide 1
Glyburide
Ligands
Europium
Cell signaling
Pentetic Acid
Cell Surface Receptors
Fluorescence microscopy
G-Protein-Coupled Receptors
Assays
Monomers
Insulin
Insulin-Secreting Cells
Endocytosis
Fluorescence Microscopy

Keywords

  • binding assays
  • fluorescence
  • lanthanides
  • molecular dynamics
  • peptidomimetics
  • solid-phase synthesis

ASJC Scopus subject areas

  • Biochemistry
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology

Cite this

Hart, N. J., Chung, W. J., Weber, C., Ananthakrishnan, K., Anderson, M., Patek, R., ... Lynch, R. (2014). Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells. ChemBioChem, 15(1), 135-145. https://doi.org/10.1002/cbic.201300375

Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells. / Hart, Nathaniel J.; Chung, Woo Jin; Weber, Craig; Ananthakrishnan, Kameswari; Anderson, Miranda; Patek, Renata; Zhang, Zhanyu; Limesand, Sean W; Vagner, Josef; Lynch, Ron.

In: ChemBioChem, Vol. 15, No. 1, 03.01.2014, p. 135-145.

Research output: Contribution to journalArticle

Hart, NJ, Chung, WJ, Weber, C, Ananthakrishnan, K, Anderson, M, Patek, R, Zhang, Z, Limesand, SW, Vagner, J & Lynch, R 2014, 'Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells', ChemBioChem, vol. 15, no. 1, pp. 135-145. https://doi.org/10.1002/cbic.201300375
Hart NJ, Chung WJ, Weber C, Ananthakrishnan K, Anderson M, Patek R et al. Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells. ChemBioChem. 2014 Jan 3;15(1):135-145. https://doi.org/10.1002/cbic.201300375
Hart, Nathaniel J. ; Chung, Woo Jin ; Weber, Craig ; Ananthakrishnan, Kameswari ; Anderson, Miranda ; Patek, Renata ; Zhang, Zhanyu ; Limesand, Sean W ; Vagner, Josef ; Lynch, Ron. / Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells. In: ChemBioChem. 2014 ; Vol. 15, No. 1. pp. 135-145.
@article{beebd82114f949849ac09c32ee516da8,
title = "Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells",
abstract = "G protein-coupled receptor (GPCR) cell signalling cascades are initiated upon binding of a specific agonist ligand to its cell surface receptor. Linking multiple heterologous ligands that simultaneously bind and potentially link different receptors on the cell surface is a unique approach to modulate cell responses. Moreover, if the target receptors are selected based on analysis of cell-specific expression of a receptor combination, then the linked binding elements might provide enhanced specificity of targeting the cell type of interest, that is, only to cells that express the complementary receptors. Two receptors whose expression is relatively specific (in combination) to insulin-secreting pancreatic β-cells are the sulfonylurea-1 (SUR1) and the glucagon-like peptide-1 (GLP-1) receptors. A heterobivalent ligand was assembled from the active fragment of GLP-1 (7-36 GLP-1) and glibenclamide, a small organic ligand for SUR1. The synthetic construct was labelled with Cy5 or europium chelated in DTPA to evaluate binding to β-cells, by using fluorescence microscopy or time-resolved saturation and competition binding assays, respectively. Once the ligand binds to β-cells, it is rapidly capped and presumably removed from the cell surface by endocytosis. The bivalent ligand had an affinity approximately fivefold higher than monomeric europium-labelled GLP-1, likely a result of cooperative binding to the complementary receptors on the βTC3 cells. The high-affinity binding was lost in the presence of either unlabelled monomer, thus demonstrating that interaction with both receptors is required for the enhanced binding at low concentrations. Importantly, bivalent enhancement was accomplished in a cell system with physiological levels of expression of the complementary receptors, thus indicating that this approach might be applicable for β-cell targeting in vivo.",
keywords = "binding assays, fluorescence, lanthanides, molecular dynamics, peptidomimetics, solid-phase synthesis",
author = "Hart, {Nathaniel J.} and Chung, {Woo Jin} and Craig Weber and Kameswari Ananthakrishnan and Miranda Anderson and Renata Patek and Zhanyu Zhang and Limesand, {Sean W} and Josef Vagner and Ron Lynch",
year = "2014",
month = "1",
day = "3",
doi = "10.1002/cbic.201300375",
language = "English (US)",
volume = "15",
pages = "135--145",
journal = "ChemBioChem",
issn = "1439-4227",
publisher = "Wiley-VCH Verlag",
number = "1",

}

TY - JOUR

T1 - Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells

AU - Hart, Nathaniel J.

AU - Chung, Woo Jin

AU - Weber, Craig

AU - Ananthakrishnan, Kameswari

AU - Anderson, Miranda

AU - Patek, Renata

AU - Zhang, Zhanyu

AU - Limesand, Sean W

AU - Vagner, Josef

AU - Lynch, Ron

PY - 2014/1/3

Y1 - 2014/1/3

N2 - G protein-coupled receptor (GPCR) cell signalling cascades are initiated upon binding of a specific agonist ligand to its cell surface receptor. Linking multiple heterologous ligands that simultaneously bind and potentially link different receptors on the cell surface is a unique approach to modulate cell responses. Moreover, if the target receptors are selected based on analysis of cell-specific expression of a receptor combination, then the linked binding elements might provide enhanced specificity of targeting the cell type of interest, that is, only to cells that express the complementary receptors. Two receptors whose expression is relatively specific (in combination) to insulin-secreting pancreatic β-cells are the sulfonylurea-1 (SUR1) and the glucagon-like peptide-1 (GLP-1) receptors. A heterobivalent ligand was assembled from the active fragment of GLP-1 (7-36 GLP-1) and glibenclamide, a small organic ligand for SUR1. The synthetic construct was labelled with Cy5 or europium chelated in DTPA to evaluate binding to β-cells, by using fluorescence microscopy or time-resolved saturation and competition binding assays, respectively. Once the ligand binds to β-cells, it is rapidly capped and presumably removed from the cell surface by endocytosis. The bivalent ligand had an affinity approximately fivefold higher than monomeric europium-labelled GLP-1, likely a result of cooperative binding to the complementary receptors on the βTC3 cells. The high-affinity binding was lost in the presence of either unlabelled monomer, thus demonstrating that interaction with both receptors is required for the enhanced binding at low concentrations. Importantly, bivalent enhancement was accomplished in a cell system with physiological levels of expression of the complementary receptors, thus indicating that this approach might be applicable for β-cell targeting in vivo.

AB - G protein-coupled receptor (GPCR) cell signalling cascades are initiated upon binding of a specific agonist ligand to its cell surface receptor. Linking multiple heterologous ligands that simultaneously bind and potentially link different receptors on the cell surface is a unique approach to modulate cell responses. Moreover, if the target receptors are selected based on analysis of cell-specific expression of a receptor combination, then the linked binding elements might provide enhanced specificity of targeting the cell type of interest, that is, only to cells that express the complementary receptors. Two receptors whose expression is relatively specific (in combination) to insulin-secreting pancreatic β-cells are the sulfonylurea-1 (SUR1) and the glucagon-like peptide-1 (GLP-1) receptors. A heterobivalent ligand was assembled from the active fragment of GLP-1 (7-36 GLP-1) and glibenclamide, a small organic ligand for SUR1. The synthetic construct was labelled with Cy5 or europium chelated in DTPA to evaluate binding to β-cells, by using fluorescence microscopy or time-resolved saturation and competition binding assays, respectively. Once the ligand binds to β-cells, it is rapidly capped and presumably removed from the cell surface by endocytosis. The bivalent ligand had an affinity approximately fivefold higher than monomeric europium-labelled GLP-1, likely a result of cooperative binding to the complementary receptors on the βTC3 cells. The high-affinity binding was lost in the presence of either unlabelled monomer, thus demonstrating that interaction with both receptors is required for the enhanced binding at low concentrations. Importantly, bivalent enhancement was accomplished in a cell system with physiological levels of expression of the complementary receptors, thus indicating that this approach might be applicable for β-cell targeting in vivo.

KW - binding assays

KW - fluorescence

KW - lanthanides

KW - molecular dynamics

KW - peptidomimetics

KW - solid-phase synthesis

UR - http://www.scopus.com/inward/record.url?scp=84890789065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890789065&partnerID=8YFLogxK

U2 - 10.1002/cbic.201300375

DO - 10.1002/cbic.201300375

M3 - Article

C2 - 24259278

AN - SCOPUS:84890789065

VL - 15

SP - 135

EP - 145

JO - ChemBioChem

JF - ChemBioChem

SN - 1439-4227

IS - 1

ER -